Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Patent
1997-01-15
2000-04-25
Mosher, Mary E.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
4241861, 4241921, 4352351, 530350, A61K 39245, C12N 700
Patent
active
06054130&
ABSTRACT:
Compositions comprising gp350 variant DNA and amino acid sequences are provided, as are vectors and host cells containing such sequences. Also provided is a process for producing homogeneous gp350 protein recombinantly and in the absence of production of gp220 protein, pharmaceutical compositions containing such protein and prophylactic treatments making use of such proteins.
REFERENCES:
patent: 4707358 (1987-11-01), Kieff et al.
patent: 5474914 (1995-12-01), Spaete
patent: 5632992 (1997-05-01), Nesburn
patent: 5648079 (1997-07-01), Burke et al.
patent: 5747039 (1998-05-01), Burke et al.
patent: 5750114 (1998-05-01), Burke et al.
patent: 5767250 (1998-06-01), Spaete
Hessing, M. et al Journal of Chromatography, vol. 599, p. 267-272, 1992.
Randle et al. 1985 "Large Scale Purification of EBV Membrane Antigen gp-340 with a Monoclonal Antibody Immunoabsorbent" Journal of Immunological Methods 77: 25-36.
Wallace et al. 1991 "Identification of two T-cell epitopes on the Candidate EBV vaccine glycoprotein go340 recognized by CD4-positive T-cell clones". Journal of Virology 65: 3821-3828.
Nemerow et al., 1987, "Identification of gp350 as the Viral Glycoprotein Mediating Attachment of Epstein-Barr Virus (EBV) to the EBV/C3d Receptor of B Cells: Sequence Homology of gp350 and C3 Complement Fragment C3d", J. Virol. 61:1416-1420.
Miller et al., 1972, "Epstein-Barr Virus: Transformation, Cytopathic Changes, and Viral Antigens in Squirrel Monkey and Marmoset Leukocytes", Proc. Natl. Acad. Sci. USA 69:383-387.
Whang et al., 1987, "Expression of the Epstein-Barr Virus gp350/220 Gene in Rodent and Primate Cells", J. Virol. 61:1796-1807.
Motz et al., 1986, "Expression of the Epstein-Barr Virus Major Membrane Proteins in Chinese Hamster Ovary Cells", Gene 44:353-359.
Emini et al., 1988, "Antigenic Analysis of the Epstein-Barr Virus Major Membrane Antigen (gp350/220) Expressed in Yeast and Mammalian Cells: Implications for the Development of a Subunit Vaccine", Virol. 166:387-393.
Madej et al., 1992, "Purification and characterization of Epstein-Barr Virus gp350/220 Produced by a Bovine Papillomavirus Virus Expression Vector System", Vaccine 10:777-781.
Finerty et al., 1992, "Protective Immunization Against Epstein-Barr Virus-Induced Disease in Cottontop Tamarins Using the Virus Envelope Glycoprotein gp340 Produced from a Bovine Papilloma Expression Vector", J. Gen. Virol. 73:449-453.
David et al., 1988, "Efficient Purification of Epstein-Barr Virus Membrane Antigen gp340 by Fast Protein Liquid Chromatography", J. Immunol. Meth. 108:231-236.
Morgan et al., 1988, "Recombinant Vaccinia Virus Expressing Epstein-Barr Virus Glycoprotein gp340 Protects Cottontop Tamarinds Against EB Virus-Induced Malignant Lymphomas", J. Med. Virol. 25:189-195.
Mackett and Arrand, 1985, "Recombinant Vaccinia Virus Induces Neutralising Antibodies in Rabbits Against Epstein-Barr Virus Membrane Antigen gp340", EMBO J. 4:3229-3234.
Mackett et al., 1986, "Characterization of Vaccinia Virus Recombinants Expressing the Epstein-Barr Virus Membrane Antigen gp340", Vaccines 86:293-297 (Cold Spring Harbor Laboratory).
Treisman et al., 1981, "Transformation of Rat Cells by an Altered Polyoma Virus Genome Expressing Only the Middle-T Protein", Nature 292:595-600.
Ryu et al., 1989, "Simian Virus 40 Late Transcripts Lacking Excisable Intervening Sequences are Defective in Both Stability in the Nucleus and Transport to the Cytoplasm", J. Virol. 63:4386-4394.
Gruss et al., 1980, "Rescue of a Splicing Defective Mutant by Insertion of an Heterologous Intron", Nature 286:634-637.
Straus et al., 1993, "Epstein-Barr Virus Infections: Biology, Pathogenesis, and Management", Ann. Internal MEd. 188:45-58.
Baer et al., 1984, "DNA Sequence and Expression of the B95-8 Epstein-Barr Virus Genome", Nature 310;207-211.
Beisel et al., 1985, "Two Major Outer Envelope Glycoproteins of Epstein-Barr Virus are Encoded by the Same Gene", J. Virol. 54:665-674.
Biggin et al., 1984, "Transcription and DNA Sequence of the BamHl L Fragment of B95-8 Epstein-Barr Virus", EMNBO J. 3:1083-1090.
Lees et al., 1993, "The Epstein-Barr Virus Candidate Vaccine Antigen gp340/220 is Highly Conserved Between Virus Types A and B", Virol. 195:578-586.
Thorley et al., 1980, "Monoclonal Antibodies Against the Major Glycoprotein (gp340/220) of Epstein-Barr Virus Neutralize Infectivity", Proc. Natl. Acad. Sci. USA 77:5307-5311.
Mount, 1982, "A Catalog of Splice Junction Sequences" Nucl. Acids Res. 10:459-472.
Tartaglia et al., 1990, "Poxvirus-Based Vectors as Vaccine Candidates", Crit. Rev. Immunol. 10:13-30.
Manservigi et al., 1980, "Protection from Herpes Simplex Virus Type I Lethal and Latent Infections by Secreted Recombinant Glycoprotein B Constitutively Expressed in Human Cells with a BK Virus Episomal Vector", J. Virol. 64:431-436.
Rose and Bergmann, 1982, "Expression from Cloned cDNA of Cell-Surface and Secreted Forms of the Glycoprotein of Vesicular Stomatitis Virus in Eucaryotic Cells", Cell 30:753-762.
Gething and Sambrook, 1982, "Construction of Influenza Haemagglutinin Genes that Code for Intracellular and Secreted Forms of the Protein", Nature 300:598-603.
Spaete et al., 1991, "CMV (Towne) Glycoprotein H (gH) is Complexed with GRP78 and GRP94", in: Progress in Cytomegalovirus Research, M.P. Landini, ed., Elsevier Science Publishers, B.V., pp. 133-136.
Spaete et al., 1993, "Coexpression of Truncated Human Cytomegalovirus gH with the UL115 Gene Product or the Truncated Human Fibroblast Growth Factor Receptor Results in Transport of gH to the Cell Surface", Virol. 193:853-861.
Pachi et al., 1989, "The Human Cytomegaiovirus Strain Towne Glycoprotein H Gene Encodes Glycoprotein p86", Virol. 169:418-426.
Spaete et al., 1990, "Sequence Requirements for Proteolytic Processing of Glycoprotein B of Human Cytomegalovirus Strain Towne", J. Virol. 64:2922-2931.
Spaete et al., 1988, "Human Cytomegalovirus Strain Towne Glycoprotein B is Processed by Proteolytic Cleavage", Virol. 167:207-225.
Spaete, 1991, "A Recombinant Subunit Vaccine Approach to HCMV Vaccine Development", Transplant. Proc. 23(Suppl. 3):90-96.
Pachl et al., 1990, "Expression and Characterization of Recombinant Forms of CMV (Towne) Glycoprotein H", The 15th International Herpesvirus Workshop, p. 244 (abstract).
Tosoni-Pittoni et al., 1989, "Complete Characterization of the Gene Coding for the Epstein-Barr Virus Major Membrane Antigen gp220/340 and Selective Expression of a Secreted Form of gp220", Biochem. Biophys. Res. Comm. 158:676-684.
Complaint for Misappropriation of Trade Secrets, Unfair Competition, Breach of Contract filed Jul. 1, 1996.
Jackman Winthrop T.
Spaete Richard
LandOfFree
Non-splicing variants of gp350/220 does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Non-splicing variants of gp350/220, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Non-splicing variants of gp350/220 will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-991303